10 April 2021: Articles
Hodgkin Lymphoma-Associated Superior Vena Cava Syndrome: A Case Report and Review of the Literature
Rare coexistence of disease or pathology
Ruoning Ni A* , Mahmoud Amr A , Abhishek Kalla ADOI: 10.12659/AJCR.929437
Am J Case Rep 2021; 22:e929437
Table 2. Summary of patients with superior vena cava syndrome associated with Hodgkin lymphoma.
| Case | Age | Gender | Subtype | Stage | Treatment | Steroid use | Follow up | Note |
|---|---|---|---|---|---|---|---|---|
| Rizvi, et al 2012 []12 | 14 | Female | Mixed cellularity | II | Doxorubicin, bleomycin, vinblastine and dacarbazine plus radiotherapy | Dexamethasone after biopsy | Unclear time: remission | |
| Ramyar, et al 2010 []13 | 16 | Female | Lymphocytic predominant | IV | Adriamycin, bleomycin, vinblastine, dacarbazine. Radiotherapy after development of SVC syndrome | No | Month 4: patient developed heart failure with reduced ejection fraction, severe valvular dysfunction and pericardial effusion. Year 1: no serious problem | Few weeks after chemotherapy, the patient developed SVC syndrome |
| Kentos, et al 2005 []14 | 22 | Male | Nodular sclerosis | IIIB | Year 1: 6 cycles of doxorubicin, bleomycin, vinblastine and dacarbazine, with radiotherapy. Year 3: recur, 3 cycles of etoposide, vinblastine, cytarabine and cisplatin, plus carmustine, etoposide, cytarabine and melphalan and autologous hematopoietic stem cell transplantation. Year 4: recur, 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone. Year 6: recur, left upper pulmonary lobectomy with radical mediastinal lymph node dissection | Received at Year 4 | Year 9: remission | |
| Saraya, et al 2008 []15 | 47 | Male | Nodular sclerosis | IIIB | 6 courses of doxorubicin, bleomycin, vinblastine, dacarbazine | No | Course 6: responds well | |
| Yellin, et al 1992 []16 | 7 | Male | Nodular sclerosis | IIIB | Not mentioned | Not mentioned | After 1 year 3 months: alive | |
| Kantarci, et al 2008 []17 | 8 | Female | Non detailed | Not mentioned | Not mentioned | Not mentioned | Non detailed | Numerous collateral venous pathways |
| Yellin, et al 1992 []16 | 11 | Male | Nodular sclerosis | IIA | Not mentioned | Not mentioned | After 1 year and 5 months: alive | |
| Ingram, et al 1990 []11 | 13 | Male | Nodular sclerosis | Not mentioned | Not mentioned | Not mentioned | Month 124: complete remission | |
| Ingram, et al 1990 []11 | 16 | Male | Nodular sclerosis | Not mentioned | Not mentioned | Not mentioned | Month 28: alive with recurrence | |
| Kim, et al 2015 []18 | 21 | Female | Not mentioned | Not mentioned | Not mentioned | Not mentioned | Not mentioned | Pseudovertebral enhancement |
| Geller, et al 1963 []19 | 25 | Female | Not mentioned | Not mentioned | 29 mg HN2 plus radiotherapy | No | Not mentioned | |
| Bach, et al 2011 []20 | 27 | Male | Not mentioned | Not mentioned | Not mentioned | Not mentioned | Not mentioned | Recurrent, with central venous catheter placed to pericardia-cophrenic vein |
| Pattara-tuma, et al 2016 []21 | 31 | Female | Not mentioned | Not mentioned | Not mentioned | Systemic corticosteroids given for asthma | Not mentioned | 30 weeks of gestation |
| Srinathan, et al 2005 []22 | 35 | Male | Not mentioned | Not mentioned | Stent placement plus chemotherapy | No | Year 2: remission | Developing stent migration to right atrium and sepsis |
| Eren, et al 2005 []23 | 40 | Male | Not mentioned | Not mentioned | Not mentioned | Not mentioned | Not mentioned | |
| Adelstein, et al 1988 []24 | Not mentioned | Not mentioned | Lymphocyte depleted | II | Not mentioned | Not mentioned | Not mentioned | |
| Porte, et al 2000 []25 | Not mentioned | Not mentioned | Not mentioned | Not mentioned | Not mentioned | Not mentioned | Not mentioned | |
| Mehta, et al 2014 []26 | 69 (17 at diagnosis) | Female | Not mentioned | Not mentioned | Radiotherapy Year 7: lymph node resection plus radiotherapy for recurrence Year 43: right subclavian artery bypass for stenosis | Not mentioned | Year 7: remission | Radiotherapy-induced extensive venous fibrosis |
| Kostopoulou, et al 2008 []27 | 56 (48 at diagnosis) | Female | Not mentioned | Not mentioned | High dose chemotherapy, including ifosfamide, carboplatin and etoposide, plus autologous bone marrow transplantation plus mediastinal irradiation, status post port-a-cath placement due to multiple recurrence | No | Year 8: partial remission | SVC syndrome after 8 years with thrombosis at the tip of port-a-cath |
| Davis, et al 2011 []28 | 52 | Male | Not mentioned | Not mentioned | 6 cycles of chemotherapy plus radiotherapy | Not mentioned | Not mentioned | Radiation-induced extensive venous fibrosis |
| Fichelle, et al 2018 []29 | 53 | Female | Not mentioned | Not mentioned | Year 1: radiotherapy with complete remissionYear 21: central venous catheter placed for chemotherapy for breast cancerYear 40: presence of SVC syndrome, with no sign of tumor recurrence | Not mentioned | Year 50: clinically stable | SVC syndrome developed after central line placement without HL recurrence |